[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-small-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-small-cell-carcinoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100614189","phase-2-hypofractionated-radiotherapy-for-the-treatment-of-locally-advanced-cervical-cancer-in-uganda-100614189",false,"NCT07276360","Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","Phase II Randomized Non-Inferiority Trial of Hypofractionated Radiotherapy for Locally Advanced Cervical Cancer in Uganda","HypoRTCx-UG","Inclusion Criteria:\n\n* Females aged 18 years or older\n* Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix without prior treatment\n* Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3, IIA, IIB, IIIA, IIIB, or IIIC\n* Able to provide written informed consent in English, Luganda, Runyankole, or Lango\n* Willing to attend post-treatment follow-up for up to 12 months\n* Fit for concurrent chemotherapy with cisplatin\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2\n* Absolute neutrophil count ≥ 1,500 cells\u002Fmm\\^3 (1.5 x 10\\^9\u002FL)\n* Platelets ≥ 100,000 cells\u002Fmm\\^3 (100 x 10\\^9\u002FL)\n* Hemoglobin ≥ 9.0 g\u002FdL\n* Leukocyte count ≥ 4,000 cells\u002Fmm\\^3 (4.0 x 10\\^9\u002FL)\n* Creatinine clearance \\> 60 mL\u002Fmins, calculated using the Cockcroft-gault equation for women\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 times the upper limit of normal (ULN)\n* Total bilirubin \\\u003C 2 x ULN unless attributed to the use of antiretroviral therapy (ART)\n* HIV-positive participants must be on a stable ART regimen for at least 6 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Prior hysterectomy. Women with previous total or subtotal hysterectomy have no cervix, and hence the anatomical changes have an impact on the radiotherapy field, and dose prescriptions because they tend to have a higher risk for bowel toxicity from pelvic radiotherapy. Therefore, these women will be excluded due to the likely impact on the results of our study intervention\n* Clinical and\u002For radiological evidence of distant metastases\n* Prior pelvic or abdominal radiotherapy\n* Presence of bilateral hip prosthesis that could interfere with radiotherapy treatment\n* History of inflammatory bowel disease or any other condition that could complicate radiotherapy treatment\n* Participants who are pregnant at the time of enrollment. Pregnant women have a potential risk of radiation exposure to developing fetus, which may result in fetal malformations, growth retardation, or even fatal death. Secondly, their physiological changes alter the pharmacokinetics and pharmacodynamics of concurrent chemotherapy. Therefore, to protect the health of the mother and the unborn child, pregnant women will be excluded from the study. Patients who are found to be pregnant after enrollment will have the study procedures terminated\n* Concurrent untreated invasive malignancy\n* Uncontrolled concurrent medical\u002Fpsychiatric diagnosis that would limit compliance with study requirements\n* Uncontrolled HIV infection, especially HIV viral load \\> 2,000 copies\u002FmL\n* Participants with CD4 counts \\\u003C 200 cells\u002Fmm\\^3","FEMALE","18 Years",{"count":20,"type":21},278,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II trial compares the effect of hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) when given in combination with cisplatin and brachytherapy in patients with stage IB3, II, or III cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. CFRT delivers the total dose of radiation over the amount of time according to standard practice. HFRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HFRT shortens treatment duration and may reduce costs and may improve the completion rates. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HFRT may be safe, tolerable, and\u002For as effective as CFRT when given in combination with cisplatin and brachytherapy in treating patients with stage IB3, II or III cervical cancer.",[27,28,29,30,31],"Cervical Cancer","Cervix Cancer","Cervical Adenocarcinoma","Cervical Small Cell Carcinoma","Cervical Adenosquamous Carcinoma",[33,34,35,36],"Cervical cancer","Radiotherapy","Hypofractionation","Uganda","RECRUITING","2026-03-26",{"date":40,"type":41},"2026-03-27","ACTUAL",{"date":43,"type":41},"2026-03-11",{"date":45,"type":21},"2029-01-02",{"name":47,"class":48},"Uganda Cancer Institute","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":49},"100418006","establishing-a-tumor-registry-for-patients-with-neuroendocrine-carcinoma-of-the-cervix-100418006","NCT04723095","Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix","NeCTuR","Inclusion Criteria:\n\n* Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:\n\n  * Small cell neuroendocrine carcinoma\n  * Large cell neuroendocrine carcinoma\n  * Undifferentiated high-grade neuroendocrine carcinoma\n* Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study\n* Patients with all stages of disease are considered eligible\n* Patients who do not speak English can be eligible if accompanied by an institutional interpreter\n* Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible\n* Patient may be residents of any country and be of any ethnic background\n* Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website\n* Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate\n* Next of kin or legal authorized representatives of patients must read and speak English\n\nExclusion Criteria:\n\n* Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors","ALL",{"count":59,"type":21},750,"OBSERVATIONAL","This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.",[63,64,30,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Cervical Large Cell Neuroendocrine Carcinoma","Cervical Neuroendocrine Carcinoma","Cervical Undifferentiated Carcinoma","Stage I Cervical Cancer AJCC v8","Stage IA Cervical Cancer AJCC v8","Stage IA1 Cervical Cancer AJCC v8","Stage IA2 Cervical Cancer AJCC v8","Stage IB Cervical Cancer AJCC v8","Stage IB1 Cervical Cancer AJCC v8","Stage IB2 Cervical Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8","Stage IVB Cervical Cancer AJCC v8","2026-03-03",{"date":86,"type":41},"2026-03-05",{"date":88,"type":41},"2013-05-16",{"date":90,"type":21},"2044-01-01",{"name":92,"class":48},"M.D. Anderson Cancer Center"]